RxDoctor Payments Data

Courtney Dawson, MD

Family Medicine · Hurt, VANPI 1881188431

Payments from drug & device makers

$307in general payments, 2019–2025

Across 17 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$50
  • Otsuka America Pharmaceutical, Inc.$46
  • Novo Nordisk$43
  • Lilly USA, LLC$38
  • Corcept Therapeutics$36
  • ARS Pharmaceuticals Operations, Inc.$29
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$307 in reported general payments places this provider in the 50th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$146,247
Medicare patients
394
Services billed
2,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$138,747
OzempicSemaglutide86$100,411
TrulicityDulaglutide93$94,866
FarxigaDapagliflozin Propanediol62$77,978
XareltoRivaroxaban78$64,722
JardianceEmpagliflozin62$58,906
RybelsusSemaglutide30$46,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$27,888
JanuviaSitagliptin Phosphate25$27,486
CreonLipase/Protease/Amylase11$18,250
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$17,765
Lantus SolostarInsulin Glargine,hum.Rec.Anlog88$14,672
Novolog FlexpenInsulin Aspart63$13,499
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$11,361
MyrbetriqMirabegron14$10,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$43$146,491116 claims
PfizerEliquis$15$138,747163 claims
Lilly USA, LLCTrulicity$38$94,86693 claims
AbbVieCreon$20$18,25011 claims
Astellas Pharma US IncMyrbetriq$15$10,34314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Hurt

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →